» Articles » PMID: 10528114

Apolipoprotein E and Beta-amyloid Levels in the Hippocampus and Frontal Cortex of Alzheimer's Disease Subjects Are Disease-related and Apolipoprotein E Genotype Dependent

Overview
Journal Brain Res
Specialty Neurology
Date 1999 Oct 21
PMID 10528114
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The epsilon4 allele of apolipoprotein E (apoE) is associated with increased risk for the development of Alzheimer's disease (AD), possibly due to interactions with the beta-amyloid (Abeta) protein. The mechanism by which these two proteins are linked to AD is still unclear. To further assess their potential relationship with the disease, we have determined levels of apoE and Abeta isoforms from three brain regions of neuropathologically confirmed AD and non-AD tissue. In two brain regions affected by AD neuropathology, the hippocampus and frontal cortex, apoE levels were found to be decreased while Abeta(1-40) levels were increased. Levels of apoE were unchanged in AD cerebellum. Furthermore, levels of apoE and Abeta(1-40) were found to be apoE genotype dependent, with lowest levels of apoE and highest levels of Abeta(1-40) occurring in epsilon4 allele carriers. These results suggest that reduction in apoE levels may give rise to increased deposition of amyloid peptides in AD brain.

Citing Articles

The novel estrogen receptor beta agonist EGX358 and genotype influence memory, vasomotor, and anxiety outcomes in an Alzheimer's mouse model.

Schwabe M, Fleischer A, Kuehn R, Chaudhury S, York J, Sem D Front Aging Neurosci. 2024; 16:1477045.

PMID: 39629477 PMC: 11613887. DOI: 10.3389/fnagi.2024.1477045.


Updates in Alzheimer's disease: from basic research to diagnosis and therapies.

Liu E, Zhang Y, Wang J Transl Neurodegener. 2024; 13(1):45.

PMID: 39232848 PMC: 11373277. DOI: 10.1186/s40035-024-00432-x.


Nanomedicine: A New Frontier in Alzheimer's Disease Drug Targeting.

Pathak K, Ahmad M, Saikia R, Pathak M, Sahariah J, Kalita P Cent Nerv Syst Agents Med Chem. 2024; 25(1):3-19.

PMID: 38551038 DOI: 10.2174/0118715249281331240325042642.


A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.

Valencia-Olvera A, Balu D, Bellur S, McNally T, Saleh Y, Pham D Alzheimers Res Ther. 2023; 15(1):216.

PMID: 38102668 PMC: 10722727. DOI: 10.1186/s13195-023-01353-z.


Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation.

Valencia-Olvera A, Balu D, Faulk N, Amiridis A, Wang Y, Pham C Neurotherapeutics. 2023; 20(4):1120-1137.

PMID: 37157042 PMC: 10457278. DOI: 10.1007/s13311-023-01375-3.